Inflazyme, BioSeek to collaborate to characterize selective anti-inflammatory drugs

By Lisa Kerner

Charlotte, N.C., June 26 - Inflazyme Pharmaceuticals Ltd. and BioSeek, Inc. have entered into a research collaboration whereby BioSeek will apply its proprietary BioMAP Systems to characterize the mechanisms of action of Inflazyme's Leukocyte Selective Anti-inflammatory Drugs, or LSAIDs.

Financial terms of the agreement were not disclosed.

BioMAP profiling provides in-depth characterization of drug function, including mechanism of action or secondary activities.

"Inflazyme's innovative development programs in respiratory diseases are a great fit with our BioMAP technology and expertise in inflammation and related diseases," BioSeek chief executive officer Peter Staple said in a company news release.

Located in Vancouver, B.C., Inflazyme is a biopharmaceutical company focused on respiratory and inflammatory diseases.

Based in Burlingame, Calif., BioSeek is leveraging its BioMAP Systems technology to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases and related indications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.